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Background and Aim. Although mercury is involved in several immunological diseases, nothing is known about its implication in
celiac disease. Our aim was to evaluate blood and urinary levels of mercury in celiac patients.Methods. We prospectively enrolled
30 celiac patients (20 treated with normal duodenal mucosa and 10 untreated with duodenal atrophy) and 20 healthy controls
from the same geographic area. Blood and urinary mercury concentrations were measured by means of flow injection inductively
coupled plasmamass spectrometry. Enrolled patients underwent dental chart for amalgam fillings and completed a food-frequency
questionnaire to evaluate diet and fish intake. Results. Mercury blood/urinary levels were 2.4±2.3/1.0±1.4, 10.2±6.7/2.2±3.0 and
3.7±2.7/1.3±1.2 in untreated CD, treated CD, and healthy controls, respectively. Resultingmercury levels were significantly higher
in celiac patients following a gluten-free diet. No differences were found regarding fish intake and number of amalgam fillings. No
demographic or clinical data were significantly associated with mercury levels in biologic samples. Conclusion. Data demonstrate
a fourfold increase of mercury blood levels in celiac patients following a gluten-free diet. Further studies are needed to clarify its
role in celiac mechanism.
1. Introduction
Mercury (Hg) is ubiquitous environmental heavy metal,
naturally originating from erosion of the volcanic rocks and
accumulating in the food chain. Besides its natural presence,
Hg environmental concentration is progressively increasing
due to its employ in human industry and manufactures
(medications, thermometers, blood-pressure cuffs, batteries,
switches, and fluorescent light bulbs) [1–4]. Thus, Hg is
actually considered a pollutant and, due to its deleterious
effects on humans, it is generally considered toxic especially
for the nervous system [5]. Mercury main sources for human
being are represented by fish consumption, dental amalgams,
and vaccines [4, 6]. Once in the body, Hg atoms bind
the proteic thiol groups and deposit in all tissues, where
they can remain for a long time, triggering its chronic
consequences on health [7, 8]; in fact, behind the Hg
acute intoxication syndrome (exemplified by Minamata Bay
disaster) [9], recent scientific advances have demonstrated
that Hg is a cofactor in several multifactorial diseases
(cardiovascular, neurodegenerative, and autoimmune), as a
consequence of its biological effect on inflammation and
immune system [1, 10–14]. Hg is mainly an HLA class II-
restricted immunostimulator, leading to the proliferation of
B and T lymphocytes and formation of autoantibodies and
immunocomplexes [15]. In the last decades, the concomitant
increase of autoimmune disorders and Hg environmental
pollution represents an intriguing point [16]. In particular,
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the hypothesis of Hg-autoimmunity connection appears
plausible for disorders characterized by a HLA restricted
genetic background [17, 18] as celiac disease (CD), an HLA
class II-dependent autoimmune disease of the small bowel
[19–21]. CD is a common (prevalence rate 1 : 100) chronic
enteropathy triggered, in genetically predisposed subjects
(carrying the HLA DQ2 and/or DQ8 haplotypes), by the
ingestion of gluten [19, 22, 23]. In CD, gluten induces and
fuels an immunological response inducing a small bowel
mucosa damage characterized by intraepithelial lymphocy-
tosis, crypt hyperplasia, and villous atrophy [24]. However,
other-than-gluten environmental factors are supposed to be
present in the development of CD. Among them, infectious
agents (virus) [25] and microbiota [26] have been evaluated
without conclusive data.
In this context, considering the absence of pertinent
findings, Hg role in the CD pathomechanism could be
hypothesized.
The present study aimed to evaluate the Hg levels in CD
patients.
2. Materials and Methods
2.1. Patients. From January 1, 2007, to June 6, 2010, sub-
jects signing an informed consent were consecutively and
prospectively enrolled at the “Center for Prevention and
Diagnosis of Celiac Disease” of the “Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico,” Milan, Italy. CD
diagnosis was based on the presence of serological anti-tissue
transglutaminase (tTGA, ELISA, or radioimmunoassay tests)
and/or anti-endomisium (EmA, immunofluorescence tech-
nique) IgA antibodies and a duodenal histology presenting
villous atrophy (grade 3 according to the Marsh-Oberhuber
classification) [27]. The enrolment included both newly
diagnosed and treated (following a gluten-free diet, GFD)
CD patients. Treated CD patients were compliant to the
GFD with normalization of serological tests and restoration
of the duodenal villous architecture (grade 0 according
to the Marsh-Oberhuber classification). A group of non-
CD subjects was enrolled as controls. Patients reporting an
occupational exposure to Hg were excluded such as patients
reporting renal or liver pathologies. To avoid environmental
pollution differences, all participants were resident in the
same urban area (Milan, Northern Italy).
Enrolled patients underwent an odontostomatologic visit
to evaluate dental amalgam fillings and completed an opera-
tor assisted questionnaire investigating the intake of potential
Hg containing food (fish, days of intake/month), the presence
of possible factors influencing the Hg levels (nocturnal
bruxism, chewing gum use in presence of Hg amalgams),
and the presence of symptoms possibly correlated with Hg
exposure (metallic taste, foggy mind, chronic fatigue, and
tremor) [28]. Moreover, a detailed seven-day alimentary
diary was completed by participants.
The study was approved by the ethical committee of
the “Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico.”
2.2.MercuryAnalysisofBiological Samples. TotalHg levelswere
assessed by using flow injection inductively coupled plasma





















Figure 1: Mercury (Hg) blood levels of untreated and treated celiac
(CD) patients and healthy controls. Mean, 95% confidence intervals,
and statistical significance are reported in the plot.
mass spectrometry (FI-ICP-MS) as previously described
[29, 30]. Briefly, at enrollment, fasting morning venous
peripheral whole blood samples (4mL) were collected in Hg-
free polypropylene tubes containing potassium EDTA, as an
anticoagulant. Firstmorning urine specimens (100milliliters)
were obtained and stored at +4∘C until mercury analysis.
Both blood and urine samples were delivered immediately
to the laboratory of toxicology for FI-ICP-MS Hg analysis
and were processed within 24–72 hours after collection. The
limit of detection was 0.05 micrograms per liter. Internal and
external quality-control procedures were done.
2.3. Statistical Analysis. All the assumptions were verified
using SPSS version 18 (IBM SPSS, Italy), and a 𝑃 value < 0.05
was considered statistically significant (significance level of
the tests 5%, two tails). Continuous variables were analyzed
with the ANOVA one-way variance test, Turkey’s test, or the
nonparametric Kruskal-Wallis test when indicated. Categor-
ical variables were compared by 𝜒2 or Fisher’s exact test.
Kolmogorov-Smirnov was used to assess Gaussian distribu-
tion of the data. Correlations were analysed by Pearson or
Spearman test in case ofGaussian or nonparametric variables.
3. Results
Thirty CD patients (20 treated and 10 untreated) and 20
healthy controls were enrolled. As shown in Table 1, patient
age, sex, weight, and height (bodymass index, BMI) were not
statistically different among the three investigated groups.
Details of blood and urinary Hg levels of the analysed
groups are reported in Table 2.Mercury blood levels resulting
significantly increased in treated CD patients compared to
untreated CD, as detailed in Figure 1.
The number of Hg amalgam fillings was 5.0 ± 2.9, 3.0 ±
2.8, and 3.8 ± 2.6 in untreated CD, treated CD, and healthy
controls, respectively, without a statistical difference among
the groups. The number of amalgam fillings was unrelated
to both blood and urinary Hg levels (unreported data).
Bruxism prevalence and chewing gum use were comparable
in the three aforementioned groups (five, nine, and ten cases
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Table 1: Clinical and demographic parameters of the enrolled subjects.
Untreated CD (𝑛 = 10) Treated CD (𝑛 = 20) Healthy controls (𝑛 = 20) 𝑃
Age (years) 40.4 ± 7.5 40.1 ± 9.7 39.6 ± 10.9 NS
Male/female 3/7 3/17 4/16 NS
Weight (Kg) 57.0 ± 11.2 60.2 ± 8.4 62.1 ± 10.4 NS
Height (cm) 167.7 ± 5.0 165.7 ± 6.6 169.8 ± 9.0 NS
BMI 20.2 ± 3.6 21.9 ± 3.0 21.8 ± 2.8 NS
tTGA (positive %) 100 0 0 NA
Villous atrophy (Pts %) 100 0 0 NA
GFD (years) NA 8.2 ± 8.2 NA NA
BMI: bodymass index; CD: celiac disease; NS: not significant; NA: not applicable; GFD: gluten-free diet; tTGA; tissue transglutaminase antibodies; Pts: patients.








Hg blood (𝜇g/L) 2.4 ± 2.3 10.2 ± 6.7∗ 3.7 ± 2.7
Hg urine (𝜇g/L) 1.0 ± 1.4 2.2 ± 3.0 1.3 ± 1.2
CD: celiac disease; Hg: mercury.
∗
𝑃 < 0.05 versus Hg blood levels of untreated CD and healthy controls.
affected by bruxism and two, three, and four chewing gum
users in untreated CD, treated CD, and healthy controls,
resp.).
A part from for the presence of gluten-free products in
the diet of treated CD, the weekly intake of fish and seafood,
nonalcoholic beverages, and composite food (i.e., the main
sources of dietary Hg), as obtained from the seven-day long
questionnaire, was comparable in the studied groups and did
not correlate with the Hg levels in both blood and urine. In
particular the fish intake ranged from 3 to 4 times per week
in the investigated groups (data not shown).
As showed in Figure 1, the group of treated CD patients
could be divided into two subgroups, the first composed of
11 patients with Hg blood levels ≥10 𝜇g/L and the second
composed of 9 patientswith bloodHg levels<10𝜇g/L.Among
treated CD patients with Hg blood levels ≥10 𝜇g/L, metallic
taste was reported by 36% of subjects versus 33% of patients
with Hg blood levels <10 𝜇g/L, foggy mind 45% versus 11%,
chronic fatigue 18% versus 0%, and tremor 27% versus 22%.
Although the above Hg-related symptoms were increased in
group with blood Hg levels ≥10 𝜇g/L, differences were not
statistically significant probably due to the limited number of
cases.
4. Discussion
The present study demonstrated an increase of Hg levels
in patients affected by CD following a GFD. This finding,
presented here for the first time, deserves some comments
and considerations.
As for many other autoimmune diseases, CD prevalence
is increasing in the last decade [16, 31]. In the past, CD
was considered a rare disorder of childhood, characterised
by malabsorption and growth deficiency [32]; nowadays,
it is the most frequent autoimmune chronic enteropathy
(1 : 100) in western countries and it can be diagnosed at
every age [19, 33, 34]. This “pandemia” is partially explained
by the improvement of diagnostic tests (ELISA commercial
kits for detection of anti-tissue transglutaminase antibodies)
and digestive endoscopy worldwide diffusion. A “real” CD
increase seems demonstrated by studies based on biobanked
biologic samples [35, 36]. This finding is difficult to explain
but it is clear that unknown environmental factors are
involved as suggested by studies on monozygotic twins
demonstrating 80% concordance rate for the development of
CD [37]. Celiac disease pathogenetic cascade is started by an
activation of mucosal T cells, leading to a chronic autoim-
mune reaction responsible for the typical duodenal damage
with T cell infiltration, crypt hyperplasia, and villous atrophy
[38]. This mechanism occurs exclusively in the presence of
the HLA DQ2 and/or DQ8 haplotypes [38]. During the last
years, different researchers investigated factors potentially
stimulating the onset of an overt CD or simply increasing its
risk [25, 39–41]. Previous studies investigated breast feeding
habit [42], virus infection (rotavirus) [25], and the intake of
high gluten-containing grain or the use of enzymes (bacterial
transglutaminases) in food industry [23], without conclusive
data. No environmental pollutant or toxicants have been
investigated in CD, although environmental pollution is
getting higher and higher in the last decades. Different
studies demonstrated thatHg participates in the development
of several immune disorders as membraneous nephropa-
thy [43], autoimmune glomerulonephritis [44], Wegener’s
granulomatosis [45], scleroderma [46], systemic lupus ery-
thematosus [47], pemphigus [48], and multiple sclerosis
[49]. Epidemiologic data suggest that Hg amalgam fillings
have an effect in the exacerbation and/or onset of multiple
sclerosis [47]. This connection is strengthened by the clinical
improvements reported by patients affected by Hashimoto’s
thyroiditis after Hg amalgam fillings removal [47]. Again,
Hg induces in humans the formation of different types
of autoantibodies (antinuclear, antinucleolar, anti-fibrillarin,
and anti-laminin) and its effect is particularly relevant in
diseases controlled by the major histocompatibility complex
(MHC) class II (as CD), although these data mainly come
from animal studies [1, 13, 50].
Another important point is represented by the increase
of Hg levels after duodenal mucosa normalization in treated
CD. This finding represents the first demonstration that
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duodenal atrophy could lead to a reversible Hg “malabsorp-
tion.” Actually, very few are known about the Hg trans-
port/absorption in human small bowel. Recent in vitro data
on Caco-2 cell line suggest the existence of an active Hg
transport into enterocytes although the transporter remains
unknown [51]. This “scenario” could be comparable to that
observed for iron intestinal transport when a genetically
determined hemochromatosis is present in association with
CD: the concomitant duodenal atrophy preserves patients
by iron overload and the development of clinically rele-
vant hemochromatosis, usually developing during the GFD
(i.e., duodenal normalization) [52, 53]. Interpretation of the
present finding leads to important observations: (i) intestinal
Hg absorption is mainly localized in the duodenum; (ii) Hg
seems to be absorbed by transporters mainly localised on the
apical part of the villi, typically damaged in CD. However,
another factor increasing the Hg levels could be the GFD
itself; in fact, GFD could have a positive effect favoring the
Hg release from the intracellular stores to extracellular fluids
(i.e., blood). If this process could be related to the presence
of symptoms (metallic taste, foggymind, chronic fatigue, and
tremor) resemblingHg poisoning as detected in our cohort, it
remains an interesting point to be investigated in large series
of patients.
The relevant increase of Hg blood levels in treated CD is
not justified by differences in seafood consumption and den-
tal amalgam fillings, which are considered important sources
of Hg for humans by the World Health Organization, WHO
[11]. Fish generally accumulates Hg through the alimentary
chain and for these reasons fish-eating fishes (swordfish, tuna,
etc.) aremore likelyHg-contaminated, while amalgamfillings
continuously release Hg in the mouth, especially in patients
affected by bruxism or using chewing gum [11].
Looking at these data, Hg accumulation could also be due
to a genetic predisposition of CD subjects to retain it (see also
lowHg levels in urine). In our study we analysed whole blood
and urine Hg levels, believed to be reliable marker for Hg
exposure; however this choice could have some implications.
When exposure continues, tissue levels of Hg in humans
are increased, mainly in brain (pituitary gland and cerebral
cortex), central nervous system, thyroid, and kidneys. Hence,
concentrations of Hg in blood and urine may underestimate
retention of Hg in the organism. In other words, there is the
possibility that measurements of Hg in blood and urine do
not fully reflect the real body content.
Another limitation of the study, besides the limited
number of patients, is that blood and urineHg concentrations
not always correlate with the noxious effects in humans. In
fact, response toHg is influenced by different factors inducing
the onset of the immune or neurologic alteration. These
factors are largely unknown but genetic ones are the strongly
suspected: subjects with a predisposition to accumulate Hg
in determined cells or tissues could be more susceptible to
specific toxic effects [4].
In conclusion, our study demonstrates an alteration of Hg
content in CD when a gluten-free regimen is followed. This
result could be due to an altered response to Hg exposure,
with the tendency to accumulate it. Further studies are
needed to clarify if CD genetic background could generate
“sensitivity” to Hg proinflammatory effect and inspire new
rules for the surveillance of Hg content in food.
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